Content about Fentanyl

March 18, 2013

Galena buys rights to cancer-pain drug from Orexo

Galena Biopharma has purchased rights to a treatment for breakthrough cancer pain from a Swedish drug maker, Galena said Monday.

October 16, 2012

Par to acquire 14 generics

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

August 23, 2012

AcelRx starts third phase-3 trial of drug for post-operative pain

A drug maker that specializes in pain medications started the third late-stage trial of a drug for treating pain in patients who have undergone certain surgeries.

January 23, 2012

ReportersNotebook — Chain Pharmacy, 1/30/12

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said.

January 3, 2012

FDA approves new REMS for fentanyl-based painkillers

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said Tuesday.

November 21, 2011

Impax Labs looks to market generic cancer pain drug

Drug maker Impax Labs is looking to challenge the patent protection on a drug used to treat pain related to cancer, the company said Monday.

October 17, 2011

Archimedes Pharma launches Lazanda for breakthrough cancer pain

Archimedes Pharma has launched a new drug for breakthrough cancer pain, the drug maker said Monday.

October 10, 2011

FTC clears Teva-Cephalon acquisition deal

The Federal Trade Commission has given Teva Pharmaceutical Industries the green light to acquire Frazer, Pa.-based drug maker Cephalon, but with some restrictions, Teva said.

July 21, 2011

FDA OKs REMS for Fentora, Actiq

The Food and Drug Administration has approved a risk evaluation and mitigation strategy for two painkillers made by Cephalon, the drug maker said Thursday.

April 4, 2011

ProStrakan announces U.S. launch of Abstral

A drug used to treat pain in cancer patients now is available in the United States.

March 30, 2011

Valeant seeks to buy Cephalon

Canadian drug maker Valeant Pharmaceuticals has proposed to buy Cephalon for $5.7 billion, Valeant said Tuesday.

March 25, 2011

Court: Watson's generic Fentora infringes on branded counterpart

A generic painkiller made by Watson Pharmaceuticals infringes a patent covering the branded version, a U.S. District Court ruled.

March 15, 2011

Court rules in favor of Watson in generic Fentora patent suit

A generic painkiller made by Watson Pharmaceuticals does not infringe on the patent covering the branded version, a U.S. District Court has ruled.

February 11, 2011

Mallinckrodt receives FDA approval for generic Duragesic

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

January 20, 2011

ProStrakan taps two companies to administer REMS program for Abstral

British drug maker ProStrakan Group will partner with two U.S. companies to administer its risk evaluation and mitigation strategy for a cancer pain drug.

January 10, 2011

Abstral OKed as breakthrough pain treatment for cancer patients

The Food and Drug Administration has approved a new drug for treating pain in cancer patients, the agency said Friday.

January 10, 2011

Watson's generic Fentora gets FDA approval

The Food and Drug Administration has approved a generic drug made by Watson Pharmaceuticals for cancer-related pain, Watson said Monday.

October 25, 2010

Actavis issues voluntary recall for chronic pain patches

Actavis last week recalled 18 lots of its patches designed to treat persistent, moderate to...

August 22, 2010

British drug maker to open U.S. headquarters in N.J.

British drug maker Archimedes Pharma plans to set up its U.S. headquarters in New Jersey,...